Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. (STOK) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · STOK · as of Sep 30, 2025
Ownership Breakdown
157
Institutional Holders
▲ 23 vs Q2
$1.57B
Total Inst. Value
▲ $830.07M vs Q2
62.28M
Shares Outstanding
freeFloat 79.01%
67.69M
13F Shares Held
▲ 2.14M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
STOK largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 6.87M | 11.76% | 11.76% | $161.33B | Nov 13, 2025 | ▼ 547.9K |
BLACKROCK, INC. pharmaceutical preparations | 5.99M | 10.26% | 10.26% | $140.70B | Nov 12, 2025 | ▲ 62.9K |
LYNX1 CAPITAL MANAGEMENT LP pharmaceutical preparations | 5.40M | 9.26% | 9.26% | $109.88B | Nov 13, 2025 | — held |
RTW INVESTMENTS, LP pharmaceutical preparations | 5.12M | 8.78% | 8.78% | $120.40B | Nov 14, 2025 | — held |
BAKER BROS. ADVISORS LP pharmaceutical preparations | 4.63M | 7.94% | 7.94% | $108.90B | Nov 14, 2025 | — held |
REDMILE GROUP, LLC pharmaceutical preparations | 4.18M | 7.16% | 7.16% | $98.13B | Nov 14, 2025 | ▼ 200.4K |
MORGAN STANLEY pharmaceutical preparations | 3.54M | 6.06% | 6.06% | $83.12B | May 27, 2026 | ▼ 36.9K |
TORONTO DOMINION BANK pharmaceutical preparations | 3.17M | 5.44% | 5.44% | $74.57B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 3.16M | 5.42% | 5.42% | $74.35B | Nov 7, 2025 | ▲ 217.6K |
SKORPIOS TRUST pharmaceutical preparations | 2.26M | 3.87% | 3.87% | $53.02B | Oct 29, 2025 | ▼ 1.00M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
18
Increased
+3.65M shares8
New Positions
first time holders14
Decreased
−4.55M shares0
Sold Out
fully exitedNet shares change (top 50)
891.9K
+3.65M / −4.55M
Net new holders
+12
8 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
STOK insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
8
Buy transactions
3
Sell transactions
2.67
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
TZIANABOS ARTHUR director | Jun 3, 2026 | Award | 17,786 | $29.46 | $524.0K | 17.8K | Form 4 ↗ |
Smith Julie director | Jun 3, 2026 | Award | 17,786 | $29.46 | $524.0K | 17.8K | Form 4 ↗ |
LEVIN ARTHUR A director | Jun 3, 2026 | Award | 17,786 | $29.46 | $524.0K | 17.8K | Form 4 ↗ |
Krainer Adrian R. director | Jun 3, 2026 | Award | 17,786 | $29.46 | $524.0K | 17.8K | Form 4 ↗ |
Kaye Edward M. MD director | Jun 3, 2026 | Award | 17,786 | $29.46 | $524.0K | 17.8K | Form 4 ↗ |
Harrison Seth Loring director | Jun 3, 2026 | Award | 17,786 | $29.46 | $524.0K | 17.8K | Form 4 ↗ |
Burstein Jennifer director | Jun 3, 2026 | Award | 17,786 | $29.46 | $524.0K | 17.8K | Form 4 ↗ |
Ticho Barry CHIEF MEDICAL OFFICER | Jun 1, 2026 | Sale | 1,795 | $30.58 | $54.9K | 34.8K | Form 4 ↗ |
Ticho Barry CHIEF MEDICAL OFFICER | May 1, 2026 | Sale | 2,243 | $32.79 | $73.5K | 36.6K | Form 4 ↗ |
Kahn Clare director | Apr 3, 2026 | Award | 30,782 | $32.79 | $1.01M | 30.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Stoke Therapeutics, Inc. (STOK) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 20.99%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Stoke Therapeutics, Inc. is FMR LLC, holding approximately 6.87 million shares — equal to 11.76% of outstanding shares — as of September 30, 2025.
A total of 157 institutional investors currently hold STOK stock, with a combined institutional value of approximately $1.57 billion as of the most recent 13F filing period.
Frequently asked questions
STOK ownershipStoke Therapeutics, Inc. (STOK) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is FMR LLC with a 11.76% stake. Company insiders hold 20.99%. Data sourced from SEC Form 13F as of September 30, 2025.